经典型霍奇金淋巴瘤PD-1阻断应答的外周免疫特征
研究利用TCR测序和飞行时间流式细胞术,分析CheckMate 205 II期试验中56例经典型霍奇金淋巴瘤患者接受PD-1阻断治疗的外周免疫特征。基线TCR多样性高且治疗中出现单克隆扩增的患者疗效更好,CD4+而非CD8+ TCR多样性在治疗中显著增加,应答者活化的自然杀伤细胞和新鉴定的CD3-CD68+CD4+GrB+亚群丰度增加。
要点
- 基线TCR多样性和治疗中单克隆扩增与PD-1阻断疗效相关
- 治疗中CD4+ TCR多样性显著增加,完全缓解者最明显
- 应答者活化NK细胞和CD3-CD68+CD4+GrB+亚群丰度增加
核心结论
- 近期扩增的克隆多样性CD4+ T细胞和固有免疫效应细胞在cHL的PD-1阻断疗效中起重要作用。
研究设计与样本
- 基于CheckMate 205 II期临床试验(NCT02181738)的56例cHL患者,采用TCR测序和飞行时间流式细胞术分析外周免疫特征。
主要发现
- 基线TCR repertoire多样且治疗中单克隆扩增的患者对抗PD-1治疗最有效。
- 治疗中CD4+而非CD8+ TCR多样性显著增加,完全缓解者最明显。
- 应答者活化自然杀伤细胞和新鉴定的CD3-CD68+CD4+GrB+亚群丰度增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PD-1 blockade is highly effective in classical Hodgkin lymphomas (cHLs), which exhibit frequent copy-number gains of CD274 (PD-L1) and PDC1LG2 (PD-L2) on chromosome 9p24.1. However, in this largely MHC-class-I-negative tumor, the mechanism of action of anti-PD-1 therapy remains undefined. We utilized the complementary approaches of T cell receptor (TCR) sequencing and cytometry by time-of-flight analysis to obtain a peripheral immune signature of responsiveness to PD-1 blockade in 56 patients treated in the CheckMate 205 phase II clinical trial (NCT02181738). Anti-PD-1 therapy was most effective in patients with a diverse baseline TCR repertoire and an associated expansion of singleton clones during treatment. CD4+, but not CD8+, TCR diversity significantly increased during therapy, most strikingly in patients who had achieved complete responses. Additionally, patients who responded to therapy had an increased abundance of activated natural killer cells and a newly identified CD3-CD68+CD4+GrB+ subset. These studies highlight the roles of recently expanded, clonally diverse CD4+ T cells and innate effectors in the efficacy of PD-1 blockade in cHL.
引用
- Cader FZ, Hu X, Goh WL, et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med. 2020. PMID: 32778827. doi:10.1038/s41591-020-1006-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。